# Evogene

Evogene is an other based in Rehovot, Israel.

## Overview

- **Organization type:** other
- **Headquarters:** Rehovot, Israel
- **Region:** Middle East
- **Address:** Rehovot, Israel
- **Founded:** 2002
- **Assets under management:** Undisclosed
- **Website:** www.evogene.com

## Regulatory record

- **Reports private funds:** No

## About

Evogene was founded in 2002 by researchers from the Weizmann Institute of Science to commercialize computational biology for gene discovery. The company went public on the Tel Aviv Stock Exchange in 2002 and later listed on NASDAQ (EVGN) before voluntarily delisting in 2024. Its core technology, the Gene Discovery and Optimization System (GODS), applies machine learning to predict gene functions across multiple organisms. Evogene's strategy centers on licensing its AI platform across three main verticals: agriculture (Crop Protection through its Canonic subsidiary), human microbiome (through its Biomica subsidiary), and industrial applications. The company has disclosed partnerships with Corteva Agriscience and Syngenta for crop-trait development, and with Merck for microbiome-based therapeutics. Geographically, Evogene operates from its Rehovot headquarters, with research collaborations spanning North America and Europe. As of 2024, Evogene employed approximately 120 people, with R&D comprising the majority. The firm has raised over $200 million in public equity and grants since inception, including a 2022 private placement of $12 million (per the firm's SEC filings, 2022). It also maintains a U.S. subsidiary, Evogene Inc., based in Wilmington, Delaware. No philanthropic foundation or separate operating company is publicly disclosed. Evogene's structural differentiator is its platform-as-a-service model: rather than developing its own products end-to-end, it licenses its AI-powered gene discovery engine to large partners in exchange for upfront fees, milestones, and royalties. This model reduces capital intensity while retaining upside via downstream success, a structure uncommon among pure ag-biotech firms.

## Sectors

- AgriTech & FoodTech
- AI/ML
- Digital Health
- ClimateTech

## People

- Ofer Haviv — CEO
- Dr. Ilya Persky — CFO

## Questions

### What investment stages does Evogene typically target?

Evogene does not make investments; it is an R&D company. It targets early-stage discovery (gene identification and validation) and then partners with larger firms for late-stage development and commercialization. Its platform is designed for preclinical-to-phase I readiness, after which external partners handle clinical trials and market launch.

### Which sectors does Evogene explicitly avoid?

Evogene does not publicly disclose any excluded sectors beyond the scope of its platform. Its three verticals — agriculture, human microbiome, and industrial enzymes — define its operating range. It has not pursued applications in medical devices, diagnostics, or synthetic biology outside its core gene-discovery focus.

### Who runs investment decisions at Evogene?

Investment decisions — regarding R&D prioritization, partnerships, and capital allocation — are made by the executive team led by CEO Ofer Haviv and CFO Dr. Ilya Persky, with oversight from the board of directors. The firm does not have a dedicated investment committee or CIO role; funding is raised through public offerings, private placements, and government grants.

### What is Evogene's known posture on co-investments alongside external partners?

Evogene does not engage in co-investments. Its collaborations are structured as license deals or joint R&D agreements, not equity investments. For example, its partnership with Corteva is a multi-year R&D agreement to discover insect-resistance traits, with Corteva funding development and Evogene receiving milestones and royalties (per official press release, 2021).

## Related profiles

- [ZTEST ELECTRONICS INC /FI](https://altss.com/profile/ztest-electronics-inc-fi)
- [Royale Energy, Inc.](https://altss.com/profile/royale-energy-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evogene-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology